Access to biologics for rheumatoid arthritis varies widely in Europe
This article was originally published in Scrip
There are large inequalities in access to innovative biologic rheumatoid arthritis (RA) treatments across Europe, says a new study published in the European Journal of Health Economics. Variations in drug affordability, standardised prices and health technology assessments all take their toll on uptake to varying degrees.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.